Primerica Q3 revenue rises 11% to $774.1 million; EPS up 31% to $5.72
Primerica reported third quarter 2024 results, with total revenues of $774.1 million, up 11%, and diluted EPS from continuing operations of $5.72, up 31%. The EPS figure includes a $0.52 per share net remeasurement gain from the annual actuarial assumption review, and the company also reported a net loss from discontinued operations tied to its exit from the senior health business.
Key points
- Total revenues of $774.1 million rose 11% from the third quarter of 2023; net income from continuing operations was $194.7 million, up 24%.
- Diluted EPS from continuing operations was $5.72, up 31%, including a $0.52 remeasurement gain; diluted adjusted operating EPS was $5.68, up 28%.
- Net income including discontinued operations was $164.4 million, or $4.83 diluted EPS, compared with $4.23 a year earlier.
- The Board declared a $0.90 per share dividend payable December 12, 2024, and the company repurchased $129 million of common stock during the quarter.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.